

Statement of Deficiencies	(X1) Provider/Supplier/CLIA Identification Number 24D0978828	(X3) Date Survey Completed 05/01/2024
Name of Provider or Supplier Eagan Valley Pediatrics	Street Address, City, State 14135 Cedar Ave, Apple Valley, MN	
For information on the provider's plan to correct this deficiency, please contact the provider or the state survey agency.		

(X4) ID Prefix Tag	Summary Statement of Deficiencies
D2016	<p>SUCCESSFUL PARTICIPATION CFR(s): 493.803(a)(b)(c)</p> <p>(a) Each laboratory performing nonwaived testing must successfully participate in a proficiency testing program approved by CMS, if applicable, as described in subpart I of this part for each specialty, subspecialty, and analyte or test in which the laboratory is certified under CLIA. (b) Except as specified in paragraph (c) of this section, if a laboratory fails to participate successfully in proficiency testing for a given specialty, subspecialty, analyte or test, as defined in this section, or fails to take remedial action when an individual fails gynecologic cytology, CMS imposes sanctions, as specified in subpart R of this part. (c) If a laboratory fails to perform successfully in a CMS-approved proficiency testing program, for the initial unsuccessful performance, CMS may direct the laboratory to undertake training of its personnel or to obtain technical assistance, or both, rather than imposing alternative or principle sanctions except when one or more of the following conditions exists: (1) There is immediate jeopardy to patient health and safety. (2) The laboratory fails to provide CMS or a CMS agent with satisfactory evidence that it has taken steps to correct the problem identified by the unsuccessful proficiency testing performance. (3) The laboratory has a poor compliance history.</p> <p>This CONDITION is not met as evidenced by: . Based on review of proficiency testing (PT) reports from the Center for Medicare and Medicaid Services (CMS) and the American Proficiency Institute (API), the laboratory failed to successfully participate in White Blood Cell Differential PT under the specialty of Hematology in 2023 and 2024. Finding are as follows: 1. The CMS CASPER Report 0155D and the API 2023 Hematology/Coagulation - 2nd Event Performance Summary and Comparative Evaluation and the 2024 API 2023 Hematology/Coagulation 1st Event Performance Summary and Comparative Evaluation were reviewed on May 1, 2024. The reports indicated the laboratory failed to achieve satisfactory performance for White Blood Cell Differential in two out of</p>

three consecutive testing events from 2023 and 2024 resulting in unsuccessful performance. See D2130. .

D2130

HEMATOLOGY
CFR(s): 493.851(f)

Failure to achieve satisfactory performance for the same analyte in two consecutive events or two out of three consecutive testing events is unsuccessful performance.

This STANDARD is not met as evidenced by:
. Based on review of proficiency testing (PT) reports from the Center for Medicare and Medicaid Services (CMS) and the American Proficiency Institute (API), the laboratory failed to achieve successful PT performance for White Blood Cell Differential testing in two out of three consecutive PT events in 2023 and 2024. Findings include: 1. The CMS CASPER Report 0155D, reviewed on May 1, 2024, indicated the laboratory failed to obtain a White Blood Cell Differential PT successful score of at least 80 percent in two out of three consecutive testing events in 2023 and 2024. 2. The API 2024 Hematology/Coagulation - 1st Event Performance Summary confirmed the laboratory failed to obtain a White Blood Cell Differential PT score of at least 80 percent in two out of three consecutive testing events in 2023 and 2024. -2023 2nd event 60% -2024 1st event 67% .